Correction: Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients
The PLOS One Staff · 2026
Read Correction: Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients by The PLOS One Staff (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356789.txt.
Description
Issued by the PLOS One staff in 2026, this short notice corrects an earlier study of hepatitis B reactivation during lymphoma treatment. The patients in that study had both surface antigen and viral DNA tests negative. It fixes a results table, removes a duplicated percent sign from treatment-duration data, and replaces several sentences in the abstract and results with their correct wording.
The corrected text states that reactivation rates did not differ significantly by patient gender or by how long treatment lasted. Readers who cite the original study should use these corrected figures. The underlying clinical question matters for doctors deciding how closely to monitor lymphoma patients for a hepatitis B flare during therapy.
Catalog record
| CREATOR | The PLOS One Staff |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3163 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |